TIME-2
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Sponsor study identifier
Secondary identifiers
interventional
22
1 country
11
Study Start
August 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2009
Actual (reported)Study Completion
February 2009
Actual (reported)This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2007
Date type not reportedThis date has not been verified as actual or estimated.
August 8, 2007
Actual (reported)August 9, 2007
Actual (reported)February 2009
Actual (reported)February 2009
Actual (reported)Objective Response Rate
approximately 3 months
Response rate between treatment arms and time-to-event endpoints.
Up to 24 months
A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.
A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.
High dose
Local Institution
Berkeley, California, 94704, United States
Local Institution
San Francisco, California, 94143, United States
Local Institution
Augusta, Georgia, 30912, United States
Local Institution
Baltimore, Maryland, 21201, United States
Local Institution
Boston, Massachusetts, 02215, United States
Local Institution
Omaha, Nebraska, 68114, United States
Local Institution
New York, New York, 10011, United States
Bristol-Myers Squibb
Bristol-Myers Squibb
22 participants (actual enrollment reported by the registry).
First Submitted
August 8, 2007
First Posted
August 9, 2007
Study Start
August 2007
Date type not reportedThis date has not been verified as actual or estimated.
A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin.
Mid dose, and low dose
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Local Institution
New York, New York, 10021, United States
Local Institution
Winston-Salem, North Carolina, 27157, United States
Local Institution
Pittsburgh, Pennsylvania, 15224, United States
Local Institution
Columbia, South Carolina, 29210, United States
Primary Completion
February 2009
Actual (reported)Study Completion
February 2009
Actual (reported)Last Updated
December 7, 2015
Record last verified: 2015-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: